Although previous studies in mice have indicated that concurrent deficiencies in POLΘ and ATM can be partially synthetic lethal (63), our data suggest that cyclin D1 overexpression may be a useful biomarker for combined POLΘ and ATM inhibition in cancer treatment. The gene discussed is CCND1; the disease is cancer.